Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model
Authors:
- 14 June 2012
- journal article
- Published by American Society of Hematology in Blood
- Vol. 119 (24) , 5871-5878
Abstract
Hemophilia is treated by IV replacement therapy with Factor VIII (FVIII) or Factor IX (FIX), either on demand to resolve bleeding, or as prophylaxis. Improved treatment may be provided by drugs designed for subcutaneous and less frequent administration with a reduced risk of inhibitor formation. Tissue factor pathway inhibitor (TFPI) down-regulates the initiation of coagulation by inhibition of Factor VIIa (FVIIa)/tissue factor/Factor Xa (FVIIa/TF/FXa). Blockage of TFPI inhibition may facilitate thrombin generation in a hemophilic setting. A high-affinity (KD = 25pM) mAb, mAb 2021, against TFPI was investigated. Binding of mAb 2021 to TFPI effectively prevented inhibition of FVIIa/TF/FXa and improved clot formation in hemophilia blood and plasma. The binding epitope on the Kunitz-type protease inhibitor domain 2 of TFPI was mapped by crystallography, and showed an extensive overlap with the FXa contact region highlighting a structural basis for its mechanism of action. In a rabbit hemophilia model, an intravenous or subcutaneous dose significantly reduced cuticle bleeding. mAb 2021 showed an effect comparable with that of rFVIIa. Cuticle bleeding in the model was reduced for at least 7 days by a single intravenous dose of mAb 2021. This study suggests that neutralization of TFPI by mAb 2021 may constitute a novel treatment option in hemophilia.Keywords
This publication has 26 references indexed in Scilit:
- Alternatively spliced isoforms of tissue factor pathway inhibitorThrombosis Research, 2010
- Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiencyBlood, 2008
- The Haemostatic Role of Tissue Factor Pathway InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 2008
- Expression of tissue factor pathway inhibitor by endothelial cells and plateletsTransfusion and Apheresis Science, 2008
- Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia ABlood, 2008
- Thrombin generation in factor VIII‐depleted neonatal plasma: nearly normal because of physiologically low antithrombin and tissue factor pathway inhibitorJournal of Thrombosis and Haemostasis, 2006
- Tissue factor pathway inhibitor: structure, biology and involvement in diseaseThe Journal of Pathology, 2005
- Tissue Factor Pathway Inhibitor Is Expressed by Human Monocyte–Derived MacrophagesArteriosclerosis, Thrombosis, and Vascular Biology, 1999
- The second Kunitz domain of human tissue factor pathway inhibitor: cloning, structure determination and interaction with factor Xa 1 1Edited by T. RichmondJournal of Molecular Biology, 1997
- Blocking of tissue factor pathway inhibitor (TFPl) shortens the bleeding time in rabbits with antibody induced haemophilia ABlood Coagulation & Fibrinolysis, 1995